Dr. Glenn J. Jaffe, Robert Machemer Professor of Ophthalmology at Duke University School of Medicine in Durham, NC, presented the top line results during an oral abstract session
Consideration for the acquisition will be in the form of 420,000 of Aequus common shares to be issued upon closing, and an additional 2,940,000 common shares which will
Harnessing the patient’s immune system is a promising new avenue in the fight against cancer that continues to garner significant momentum and excitement. Turnstone’s technology platform, Marabex, is
Taptiqom is a preservative-free eye drop solution (in single dose containers) of a fixed dose combination of the prostaglandin analogue tafluprost (15 micrograms/ml) and the beta-blocker timolol (5
"We were looking for a partner who has a clinical trial system that manages clinical data and automates the data capture and laboratory processes in Phase I units,"
Under the agreement, EyeGate will receive an upfront cash payment, development-based milestone payments related to the completion of development for the indication of anterior uveitis and an approval-based
Purchasers in the private placement (comprised of 33 institutional investors in China) have agreed to a lock-up period of 12 months, the same as for STA and WuXi
"Bivalirudin has become a foundation anti-thrombin for patients undergoing PCI under The Medicines Company’s fifteen-year leadership in the cath lab," said Glenn Sblendorio, President and Chief Financial Officer,
The transaction will continue to bolster Hi-Tech’s leading Sports Nutrition and Weight Loss arsenal and expand its position as the leader in Diet & Energy products in the
Under the collaboration, Celgene will have the option to license histone methyltransferase (HMT) inhibitors being developed by Epizyme against three predefined targets. Under the terms of the revised
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.